Mannkind (MNKD) Long-Term Investments (2021 - 2025)
Mannkind (MNKD) reported Long-Term Investments of $5.0 million for Q4 2025, down 8.57% year-over-year from $5.5 million in Q4 2024, and down 80.89% on a QoQ basis from $26.2 million in Q3 2025.
Mannkind (MNKD) has 5 years of Long-Term Investments data on file, last reported at $5.0 million in Q4 2025.
- Quarterly Long-Term Investments fell 8.57% year-over-year to $5.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.0 million (down 8.57% YoY) and the FY2025 annual result came in at $5.0 million, down 8.57% from the prior year.
- Long-Term Investments slipped to $5.0 million in Q4 2025 per MNKD's latest filing, from $26.2 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $70.5 million in Q1 2022 and bottomed at $492000.0 in Q1 2023.
- The 5-year median for Long-Term Investments is $13.0 million (2022), against an average of $19.0 million.
- The widest annual swing landed in 2022, when Long-Term Investments soared 4600.0%; it then sank 99.3% in 2023.
- Tracing MNKD's Long-Term Investments over 5 years: stood at $56.6 million in 2021, then slumped by 96.54% to $2.0 million in 2022, then soared by 264.86% to $7.2 million in 2023, then dropped by 23.38% to $5.5 million in 2024, then decreased by 8.57% to $5.0 million in 2025.
- Per Business Quant, the three latest MNKD Long-Term Investments figures stand at $5.0 million (Q4 2025), $26.2 million (Q3 2025), and $22.2 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.01 Mn |
| Sep 30, 2025 | 26.23 Mn |
| Jun 30, 2025 | 22.24 Mn |
| Mar 31, 2025 | 16.68 Mn |
| Dec 31, 2024 | 5.48 Mn |
| Sep 30, 2024 | 16.80 Mn |
| Jun 30, 2024 | 13.40 Mn |
| Mar 31, 2024 | 3.73 Mn |
| Dec 31, 2023 | 7.16 Mn |
| Sep 30, 2023 | 3.27 Mn |
| Jun 30, 2023 | 2.28 Mn |
| Mar 31, 2023 | 492,000.00 |
| Dec 31, 2022 | 1.96 Mn |
| Sep 30, 2022 | 12.70 Mn |
| Jun 30, 2022 | 32.60 Mn |
| Mar 31, 2022 | 70.50 Mn |
| Dec 31, 2021 | 56.62 Mn |
| Sep 30, 2021 | 42.10 Mn |
| Jun 30, 2021 | 38.95 Mn |
| Mar 31, 2021 | 1.50 Mn |